https://www.targetedonc.com/view/cartitude-4-data-imwg-guideline-make-the-case-for-second-line-car-t-in-myeloma2026-07-10T21:00:00Z2026-07-10T21:00:00Z https://www.targetedonc.com/view/lung-cancer-in-women-breaking-the-smoker-s-disease-myth-with-estelamari-rodriguez-md2026-07-10T19:00:00Z2026-07-10T19:00:00Z https://www.targetedonc.com/view/first-patient-treated-with-psma-targeted-actinium-225-alpha-emitter-in-mcrpc2026-07-10T17:00:00Z2026-07-10T17:00:00Z https://www.targetedonc.com/view/adding-thoracic-radiotherapy-to-chemo-immunotherapy-fails-in-sclc2026-07-10T16:00:00Z2026-07-10T16:00:00Z https://www.targetedonc.com/view/fda-approves-perioperative-pembrolizumab-plus-enfortumab-vedotin-for-mibc2026-07-10T15:10:00Z2026-07-10T15:10:00Z https://www.targetedonc.com/view/biotherapeutic-shows-benefit-in-reducing-immunotherapy-related-enterocolitis2026-07-10T15:00:00Z2026-07-10T15:00:00Z https://www.targetedonc.com/view/what-oncology-fellowship-is-really-like-jonathan-lee-md-and-chinmay-jani-md2026-07-10T14:00:00Z2026-07-10T14:00:00Z https://www.targetedonc.com/view/fda-approves-subcutaneous-isatuximab-for-multiple-myeloma2026-07-10T12:48:01.041Z2026-07-10T12:48:01.041Z https://www.targetedonc.com/view/fda-approves-pegfilgrastim-biosimilar-for-febrile-neutropenia2026-07-10T10:00:00Z2026-07-10T10:00:00Z https://www.targetedonc.com/view/multidisciplinary-supportive-care-and-unmet-needs-in-ros1-positive-advanced-non-small-cell-lung-cancer2026-07-10T02:36:54.019Z2026-07-10T02:36:54.019Z https://www.targetedonc.com/view/second-line-sequencing-after-earlier-generation-ros1-tkis-and-the-role-of-chemotherapy-and-immunotherapy-in-ros1-positive-advanced-non-small-cell-lung-cancer2026-07-10T02:36:52.806Z2026-07-10T02:36:52.806Z https://www.targetedonc.com/view/multidisciplinary-management-and-cns-surveillance-in-ros1-positive-advanced-non-small-cell-lung-cancer2026-07-10T02:36:51.351Z2026-07-10T02:36:51.351Z https://www.targetedonc.com/view/clinical-case-2-continued-second-line-therapy-selection-and-cns-management-in-ros1-positive-advanced-non-small-cell-lung-cancer-after-solvent-front-resistance2026-07-10T02:36:49.903Z2026-07-10T02:36:49.903Z https://www.targetedonc.com/view/clinical-case-2-ros1-positive-advanced-non-small-cell-lung-cancer-with-progression-on-first-line-therapy-and-solvent-front-resistance2026-07-10T02:36:48.350Z2026-07-10T02:36:48.350Z https://www.targetedonc.com/view/bone-directed-therapy-and-comparing-ros1-directed-tkis-in-ros1-positive-advanced-non-small-cell-lung-cancer2026-07-10T02:36:47.045Z2026-07-10T02:36:47.045Z https://www.targetedonc.com/view/clinical-case-1-continued-frontline-treatment-selection-and-monitoring-in-ros1-positive-advanced-non-small-cell-lung-cancer2026-07-10T02:36:45.600Z2026-07-10T02:36:45.600Z https://www.targetedonc.com/view/clinical-case-1-newly-diagnosed-patient-with-ros1-positive-advanced-non-small-cell-lung-cancer-and-high-pd-l12026-07-10T02:36:44.107Z2026-07-10T02:36:44.107Z https://www.targetedonc.com/view/molecular-profiling-nuances-in-ros1-positive-non-small-cell-lung-cancer-pd-l1-tmb-and-testing-workflow2026-07-10T02:36:42.356Z2026-07-10T02:36:42.356Z https://www.targetedonc.com/view/patient-centered-factors-influencing-frontline-treatment-decisions-in-ros1-positive-advanced-non-small-cell-lung-cancer-cns-activity-toxicity-and-access2026-07-10T02:36:40.615Z2026-07-10T02:36:40.615Z https://www.targetedonc.com/view/second-line-considerations-in-post-hydroxyurea-high-risk-pv2026-07-09T21:00:00Z2026-07-09T21:00:00Z https://www.targetedonc.com/view/fda-clears-ind-for-next-gen-oncolytic-virus-ugn-501-in-nmibc2026-07-09T19:00:00Z2026-07-09T19:00:00Z https://www.targetedonc.com/view/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc2026-07-09T18:00:00Z2026-07-09T18:00:00Z https://www.targetedonc.com/view/golcadomide-offers-potential-outpatient-option-for-relapsed-follicular-lymphoma2026-07-09T17:00:00Z2026-07-09T17:00:00Z https://www.targetedonc.com/view/diagnostic-to-identify-pten-deficiency-launched-for-patients-with-prostate-cancer2026-07-09T15:00:00Z2026-07-09T15:00:00Z https://www.targetedonc.com/view/advanced-renal-cell-carcinoma-comparing-frontline-io-tki-combination-regimens2026-07-09T12:05:00Z2026-07-09T12:05:00Z https://www.targetedonc.com/view/advanced-renal-cell-carcinoma-selecting-between-io-tki-and-io-io-combination-therapy2026-07-09T12:00:00Z2026-07-09T12:00:00Z https://www.targetedonc.com/view/ateganosine-plus-cemiplimab-shows-90-5-disease-control-in-pretreated-nsclc2026-07-09T10:00:00Z2026-07-09T10:00:00Z https://www.targetedonc.com/view/fda-accepts-nda-for-varegacestat-in-desmoid-tumors2026-07-08T17:22:31.601Z2026-07-08T17:22:31.601Z https://www.targetedonc.com/view/oral-celmod-golcadomide-advances-in-relapsed-fl2026-07-08T17:00:00Z2026-07-08T17:00:00Z https://www.targetedonc.com/view/implementing-a-bispecific-antibody-program-in-community-oncology-insights-from-the-american-oncology-network2026-07-08T16:00:00Z2026-07-08T16:00:00Z https://www.targetedonc.com/view/the-evolution-of-treatment-goals-in-immune-thrombocytopenia2026-07-08T14:00:00Z2026-07-08T14:00:00Z https://www.targetedonc.com/view/after-the-first-tki-fails-sequencing-challenges-in-ros1-positive-nsclc2026-07-08T10:00:00Z2026-07-08T10:00:00Z https://www.targetedonc.com/view/oncologists-consider-treatment-duration-and-new-options-in-progressive-desmoid-tumors2026-07-07T21:00:00Z2026-07-07T21:00:00Z https://www.targetedonc.com/view/further-monumental-3-follow-up-needed-for-triplet-regimen-in-relapsed-myeloma2026-07-07T19:30:00Z2026-07-07T19:30:00Z https://www.targetedonc.com/view/cms-proposes-cut-to-340b-drug-payments-in-2027-outpatient-rule2026-07-07T17:00:00Z2026-07-07T17:00:00Z https://www.targetedonc.com/view/adagrasib-plus-cetuximab-falls-short-in-kras-g12c-mutated-colorectal-cancer2026-07-07T16:00:00Z2026-07-07T16:00:00Z https://www.targetedonc.com/view/fda-rejects-manganese-chloride-tetrahydrate-for-liver-mri-in-renal-impairment2026-07-07T13:22:00Z2026-07-07T13:22:00Z https://www.targetedonc.com/view/navigating-the-nuances-of-post-esa-treatment-in-lower-risk-mds2026-07-06T22:00:00Z2026-07-06T22:00:00Z https://www.targetedonc.com/view/the-growing-rationale-for-earlier-targeting-of-gprc5d-in-multiple-myeloma2026-07-06T18:30:00Z2026-07-06T18:30:00Z https://www.targetedonc.com/view/botensilimab-plus-balstilimab-yields-33-os-rate-at-3-years-in-mcrc2026-07-06T17:00:00Z2026-07-06T17:00:00Z https://www.targetedonc.com/view/fda-oks-prostact-trial-part-2-protocol-for-metastatic-prostate-cancer2026-07-06T16:00:00Z2026-07-06T16:00:00Z https://www.targetedonc.com/view/molecular-subtype-not-treatment-sequence-drives-low-grade-glioma-survival2026-07-06T14:30:00Z2026-07-06T14:30:00Z https://www.targetedonc.com/view/divarasib-improves-survival-vs-approved-kras-g12c-inhibitors-in-nsclc2026-07-05T18:19:50.208Z2026-07-05T18:20:07.599Z https://www.targetedonc.com/view/how-a-virtual-behavioral-health-program-is-reaching-patients-with-cancer-who-need-it-most2026-07-05T10:00:00Z2026-07-05T10:00:00Z https://www.targetedonc.com/view/speed-is-the-story-how-sequencing-the-human-genome-transformed-cancer-care2026-07-04T10:00:00Z2026-07-04T10:00:00Z https://www.targetedonc.com/view/examining-the-strongest-options-for-heavily-pretreated-myeloma-after-bispecific-therapy2026-07-03T17:00:00Z2026-07-03T17:00:00Z https://www.targetedonc.com/view/zoldonrasib-combos-including-with-daraxonrasib-yield-high-response-rates-in-pdac2026-07-03T15:17:02.903Z2026-07-03T15:17:02.903Z https://www.targetedonc.com/view/lung-cancer-news-roundup-june-20262026-07-03T14:00:00Z2026-07-03T14:00:00Z https://www.targetedonc.com/view/new-research-links-food-access-to-breast-cancer-biology2026-07-03T10:00:00Z2026-07-03T10:00:00Z https://www.targetedonc.com/view/choosing-among-frontline-io-tki-regimens-in-advanced-rcc2026-07-02T21:00:00Z2026-07-02T21:00:00Z https://www.targetedonc.com/view/three-regimens-show-comparable-efficacy-in-preventing-gvhd-in-haplo-pbsct2026-07-02T20:00:00Z2026-07-02T20:00:00Z https://www.targetedonc.com/view/ziftomenib-expands-role-in-relapsed-refractory-npm1-mutated-aml2026-07-02T18:00:00Z2026-07-02T18:00:00Z https://www.targetedonc.com/view/breast-cancer-news-roundup-june-20262026-07-02T17:00:00Z2026-07-02T17:00:00Z https://www.targetedonc.com/view/q2-2026-in-oncology-a-look-back-at-fda-approvals-and-decisions2026-07-02T10:00:00Z2026-07-02T10:00:00Z https://www.targetedonc.com/view/new-considerations-arise-in-sequencing-after-second-relapse-in-multiple-myeloma2026-07-01T21:00:00Z2026-07-01T21:00:00Z https://www.targetedonc.com/view/sc-amivantamab-plus-lazertinib-builds-on-evolving-frontline-paradigm-in-egfr-nsclc2026-07-01T18:20:40.248Z2026-07-01T18:20:40.248Z https://www.targetedonc.com/view/practical-considerations-with-frontline-sc-amivantamab-plus-lazertinib-in-egfr-nsclc2026-07-01T18:20:27.014Z2026-07-01T18:20:27.014Z https://www.targetedonc.com/view/prophylactic-anticoagulation-with-amivantamab-plus-lazertinib-in-egfr-nsclc2026-07-01T18:20:14.281Z2026-07-01T18:20:14.281Z https://www.targetedonc.com/view/optimal-patient-management-with-sc-amivantamab-plus-lazertinib-in-frontline-egfr-nsclc2026-07-01T18:19:59.401Z2026-07-01T18:19:59.401Z https://www.targetedonc.com/view/tolerability-of-sc-amivantamab-plus-lazertinib-in-frontline-egfr-nsclc2026-07-01T18:19:39.673Z2026-07-01T18:19:39.673Z https://www.targetedonc.com/view/durability-of-sc-amivantamab-plus-lazertinib-in-frontline-egfr-nsclc2026-07-01T18:19:18.657Z2026-07-01T18:19:18.657Z https://www.targetedonc.com/view/chemo-free-zanubrutinib-combo-bests-bendamustine-in-frontline-mcl2026-07-01T18:00:00Z2026-07-01T18:00:00Z https://www.targetedonc.com/view/merlin-cp-gep-receives-breakthrough-device-designation-to-assess-need-for-melanoma-slnb2026-07-01T15:00:00Z2026-07-01T15:00:00Z https://www.targetedonc.com/view/june-2026-in-oncology-a-look-back-at-fda-approvals-and-decisions2026-07-01T10:00:00Z2026-07-01T10:00:00Z https://www.targetedonc.com/view/drowning-in-data-how-oncologists-are-coping-with-information-overload-in-the-ai-era2026-07-01T09:00:00Z2026-07-01T09:00:00Z https://www.targetedonc.com/view/orca-t-gains-fda-approval-in-mds-aml-and-all2026-06-30T22:22:00Z2026-06-30T22:22:00Z https://www.targetedonc.com/view/insight-trial-de-escalating-immunotherapy-after-lung-cancer-pcr2026-06-30T21:00:00Z2026-06-30T21:00:00Z https://www.targetedonc.com/view/factors-affecting-first-line-ici-choice-in-her2-negative-gastric-cancer2026-06-30T21:00:00Z2026-06-30T21:00:00Z https://www.targetedonc.com/view/experts-weigh-fixed-duration-approaches-in-frontline-cll2026-06-30T16:00:00Z2026-06-30T16:00:00Z https://www.targetedonc.com/view/epcoritamab-lenalidomide-combo-cuts-progression-risk-in-r-r-dlbcl2026-06-30T15:00:00Z2026-06-30T15:00:00Z https://www.targetedonc.com/view/evolving-role-of-imdc-risk-stratification-in-first-line-treatment-selection2026-06-30T12:15:00Z2026-06-30T12:15:00Z https://www.targetedonc.com/view/advanced-renal-cell-carcinoma-building-a-personalized-first-line-treatment-algorithm2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.targetedonc.com/view/q3-2026-oncology-outlook-key-fda-decisions-to-watch2026-06-30T22:39:00.000Z2026-06-30T10:00:00Z https://www.targetedonc.com/view/navigating-treatment-selection-for-advanced-nets2026-06-29T21:00:00Z2026-06-29T21:00:00Z https://www.targetedonc.com/view/considerations-with-luspatercept-failure-in-lower-risk-mds2026-06-29T19:29:40.738Z2026-06-29T19:30:00Z https://www.targetedonc.com/view/rapid-hematologic-clearances-and-promising-bone-marrow-responses-in-al-amyloidosis2026-06-29T19:00:00Z2026-06-29T19:00:00Z https://www.targetedonc.com/view/availability-tolerability-and-drug-interactions-drive-arpi-selection-in-mhspc2026-06-29T18:00:00Z2026-06-29T18:00:00Z https://www.targetedonc.com/view/dr-munir-what-drives-frontline-cll-treatment-decisions-today-2026-06-29T17:00:00Z2026-06-29T17:00:00Z https://www.targetedonc.com/view/fda-rejects-edotreotide-pet-imaging-kit-over-manufacturing-concerns2026-06-29T16:00:00Z2026-06-29T16:00:00Z https://www.targetedonc.com/view/fda-accepts-rp1-bla-resubmission-for-advanced-melanoma2026-06-29T14:48:49.744Z2026-06-29T14:48:49.744Z https://www.targetedonc.com/view/beyond-genetic-testing-preparing-for-the-era-of-personalized-cancer-prevention2026-06-29T14:00:00Z2026-06-29T14:00:00Z https://www.targetedonc.com/view/treatment-sequencing-in-elderly-patients-with-cll2026-06-29T12:45:00Z2026-06-29T12:45:00Z https://www.targetedonc.com/view/real-world-studies-show-frontline-btki-benefit-in-more-representative-cll-populations2026-06-29T12:40:00Z2026-06-29T12:40:00Z https://www.targetedonc.com/view/impact-of-real-world-data-on-btki-treatment-selection-in-frontline-cll2026-06-29T12:35:00Z2026-06-29T12:35:00Z https://www.targetedonc.com/view/real-world-medicare-database-outcomes-with-btki-in-frontline-cll2026-06-29T12:30:00Z2026-06-29T12:30:00Z https://www.targetedonc.com/view/advice-for-community-oncologists-on-optimizing-frontline-btki-for-cll2026-06-29T12:25:00Z2026-06-29T12:25:00Z https://www.targetedonc.com/view/discussions-with-older-cll-patients-on-frontline-btki-treatment2026-06-29T12:20:00Z2026-06-29T12:20:00Z https://www.targetedonc.com/view/significance-of-having-both-real-world-and-clinical-trial-data-for-frontline-btki-in-cll2026-06-29T12:15:00Z2026-06-29T12:15:00Z https://www.targetedonc.com/view/long-term-follow-up-with-zanubrutinib-across-cll-patient-populations2026-06-29T12:10:00Z2026-06-29T12:10:00Z https://www.targetedonc.com/view/treatment-considerations-with-newly-diagnosed-older-cll-patients2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.targetedonc.com/view/long-term-data-for-continuous-btki-in-frontline-cll2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.targetedonc.com/view/fda-clears-pen-device-for-interferon-therapy-in-polycythemia-vera2026-06-29T10:00:00Z2026-06-29T10:00:00Z https://www.targetedonc.com/view/sequoia-zanubrutinib-holds-up-in-cll-s-toughest-age-group2026-06-28T15:00:00Z2026-06-28T15:00:00Z https://www.targetedonc.com/view/phase-3-trident-trial-misses-survival-end-point-in-glioblastoma2026-06-28T10:00:00Z2026-06-28T10:00:00Z https://www.targetedonc.com/view/beyond-komet-007-what-s-next-for-ziftomenib-in-aml2026-06-27T15:00:00Z2026-06-27T15:00:00Z https://www.targetedonc.com/view/gene-signature-predicts-anthracycline-benefit-in-hr-her2-breast-cancer2026-06-27T10:00:00Z2026-06-27T10:00:00Z https://www.targetedonc.com/view/oncologists-weigh-tivozanib-data-in-pretreated-metastatic-rcc2026-06-26T21:00:00Z2026-06-26T21:00:00Z https://www.targetedonc.com/view/zeidan-discusses-feasibility-of-long-term-ziftomenib-use-in-aml2026-06-26T17:00:00Z2026-06-26T17:00:00Z https://www.targetedonc.com/view/dr-goudar-on-preparing-for-the-future-of-genetic-testing-in-oncology2026-06-26T17:00:00Z2026-06-26T17:00:00Z https://www.targetedonc.com/view/fda-approves-generic-enzalutamide-tablets-including-higher-strength-options2026-06-26T15:00:00Z2026-06-26T15:00:00Z